 |
 |

Pittsburgh Compound B Retention and Verification of Amyloid Deposition
David M. Holtzman, MD
Arch Neurol. 2007;64(3):315-316.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
Making a definitive diagnosis of Alzheimer disease (AD), or more specifically determining whether the presence of amyloid plaques in the central nervous system may be contributing to the clinical phenotype in a patient with dementia, was previously possible only with brain biopsy or at autopsy. The recent development of amyloid imaging with compounds such as carbon 11 (11C)–labeled Pittsburgh Compound B (PiB) and positron emission tomography (PET) scanning is likely to ultimately change the way physicians diagnose and treat disorders in which the aggregation of β-amyloid (Aβ) plays a role.1 It has been shown in human tissue ex vivo that the amount of PiB binding correlates strongly with the amount of Aβ present as measured biochemically.2-3 Further, in tissue sections from human brain2 as well as in vivo in a transgenic mouse model with Aβ deposition,4 it appears that PiB binds to Aβ if it . . . [Full Text of this Article]AUTHOR INFORMATION
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLE
Molecular Imaging With Pittsburgh Compound B Confirmed at Autopsy: A Case Report
Brian J. Bacskai, Matthew P. Frosch, Stefanie H. Freeman, Scott B. Raymond, Jean C. Augustinack, Keith A. Johnson, Michael C. Irizarry, William E. Klunk, Chester A. Mathis, Steven T. DeKosky, Steven M. Greenberg, Bradley T. Hyman, and John H. Growdon
Arch Neurol. 2007;64(3):431-434.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
A{beta} amyloid deposition in the language system and how the brain responds
Nelissen et al.
Brain 2007;130:2055-2069.
ABSTRACT
| FULL TEXT
|